CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
Crispr Therapeutics AG (CRSP) Receives a Buy From Bank of America Securities
Leerink Partners Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $60
Analysts' Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Applied Therapeutics (APLT)
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week
Express News | CRISPR Therapeutics AG : Leerink Partners Cuts Target Price to $60 From $65
Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $57
Palantir, Crispr, and Other Stocks Cathie Wood Thinks Could Emerge Strong From a Recession -- Barrons.com
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $84
Cathie Wood Thinks These Firms Could Emerge Strong From a Recession
Express News | Needham Reiterates Buy on CRISPR Therapeutics, Maintains $84 Price Target
CRISPR Therapeutics Analyst Ratings
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
CRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should Know
Crispr Therapeutics Gets Orphan Drug Status for Lymphoma Treatment
Crispr Therapeutics Granted Orphan Status for Follicular Lymphoma Treatment
RBC Capital Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Cuts Target Price to $38
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
RBC Cuts Price Target on CRISPR Therapeutics to $38 From $48, Keeps Sector Perform, Speculative Risk
CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference